Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
Regulatory Update: GSK announces submission for a new indication for Synflorix™ in Europe
GlaxoSmithKline plc (GSK) announced today that it has submitted a regulatory application in the European Union (EU) seeking approval of an additional indication for Synflorix, a...
Read more -
GSK to acquire five million shares in Response Genetics for US$1.10 per share in cash
GlaxoSmithKline plc (LSE: GSK) today announces that it has acquired five million newly issued shares of Response Genetics Inc. (RGI) (NASDAQ: RGDX) common stock at a purchase pr...
Read more -
GSK and Theravance announce completion of the Phase III programme for once-daily LAMA/LABA (UMEC/VI) in COPD
GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the completion of the phase III programme of an investigational LAMA/LABA involving approximately 6...
Read more -
GSK announces start of Phase III programme of sirukumab in rheumatoid arthritis
GlaxoSmithKline plc (GSK) today announced that - as part of their collaboration with Janssen Biologics (Ireland) - the Phase III programme evaluating sirukumab (CNTO 136), a hum...
Read more -
GlaxoSmithKline reaches agreement to divest majority of Classic Brands in Australia for £172m
GlaxoSmithKline plc (GSK) today announced that it has reached agreement to divest the majority of its Classic Brands (25 non-promoted and genericised products) in Australia to A...
Read more -
European Commission grants marketing authorisation for pazopanib (Votrient®) in the treatment of certain advanced soft tissue sarcoma subtypes
GlaxoSmithKline plc announced today that the European Commission has granted pazopanib marketing authorisation for the treatment of patients with advanced soft tissue sarcoma (a...
Read more -
Regulatory update – GSK announces submissions in the EU and US for dabrafenib and trametinib
GlaxoSmithKline (GSK) plc today announced regulatory submissions in the European Union and United States (US) related to single-agent use of its BRAF inhibitor dabrafenib and ME...
Read more -
GSK completes acquisition of Human Genome Sciences
GlaxoSmithKline plc (LSE: GSK) today announced that it has completed its acquisition of Human Genome Sciences (NASDAQ: HGSI) for US$3.6 billion on an equity basis, or approximat...
Read more -
GSK announces acquisition of 79% of Human Genome Sciences shares; commences subsequent offering period
GlaxoSmithKline plc (LSE: GSK) today announced the results of its initial tender offer for all outstanding shares of Human Genome Sciences (NASDAQ: HGSI) for US$14.25 per share ...
Read more -
Maximuscle powers Vodafone McLaren Mercedes drivers through the 2012 Formula 1™ season
Leading sports nutrition brand continues its presence with on-car logos in Hungary
Read more -
Results announcement for the second quarter 2012
GSK delivers Q2 core EPS of 26.4p and dividend of 17p
Read more -
GSK pre-broadcast statement on BBC Panorama: “The truth about Sports Products”, 19 July 2012
GlaxoSmithKline today issued the following statement in anticipation of the BBC Panorama programme. The truth about sports products, which is scheduled to be aired this evening....
Read more -
GlaxoSmithKline and Amicus Therapeutics expand Fabry disease collaboration
Glaxo Group Limited (GSK) and Amicus Therapeutics (Nasdaq: FOLD) today announced an expansion of their collaboration to develop and commercialise the investigational pharmacolog...
Read more -
GlaxoSmithKline celebrates its role in supporting the biggest anti-doping operation in the history of the Olympic Games
GSK today marks its role as Official Laboratory Services Provider for the London 2012 Olympic and Paralympic Games by launching its first UK advertising campaign to celebrate th...
Read more -
GSK to acquire Human Genome Sciences for US$14.25 per share in cash
GlaxoSmithKline plc (LSE: GSK) and Human Genome Sciences (NASDAQ: HGSI) today announced that the companies have entered into a definitive agreement under which GSK will acquire ...
Read more -
US Regulatory Update – Tykerb® (lapatinib)
GSK plc announced today that it has withdrawn a supplemental NDA to the US FDA for Tykerb (lapatinib) in combination with trastuzumab for the treatment of patients with HER2 (Er...
Read more -
Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV
Shionogi-ViiV Healthcare LLC today announced that initial results have been received from the Phase III SINGLE (ING114467) study of the investigational integrase inhibitor dolut...
Read more -
GSK announces positive data from Harmony 8 and completion of clinical registration package for albiglutide in type 2 diabetes
GSK today announced that data have been received from the Phase III Harmony 8 study and from the event driven meta-analysis for assessment of cardiovascular safety conducted acr...
Read more -
GlaxoSmithKline concludes previously announced agreement in principle to resolve multiple investigations with US Government and numerous states
GSK today announced that it has reached an agreement with the US Government, multiple states and the District of Columbia to conclude the Companys most significant ongoing Feder...
Read more -
GSK sets 20 July for expiration of tender offer to acquire Human Genome Sciences
GlaxoSmithKline plc (LSE: GSK) today announced it has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences (NASDAQ: HGSI) for US$13.00 per...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
